1. 1) Matsuda S. Health policy in Japan—current situation and future challenges. JMA J., 2, 1–10 (2019).
2. 2) Ministry of Health, Labour and Welfare. “Report on national health expenditures.”: ‹https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/18/dl/toukei.pdf›, accessed 13 August, 2021.
3. 3) Japan Pharmaceutical Manufacturers Association. “Data book 2021.”: ‹http://www.jpma.or.jp/about/issue/gratis/databook/data/en/2021/pdf/DB2021_en_full.pdf›, accessed 13 August, 2021.
4. 4) Japan Hospital Association, All Japan Hospital Association, Japanese Association of Medicalcare Corporations. “An overview of the regular survey of hospital management 2019”: ‹https://www.hospital.or.jp/pdf/06_20191202_01.pdf›, accessed 30 September, 2021.
5. 5) Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol., 14, 381–390 (2017).